{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T11:09:07Z","timestamp":1784286547585,"version":"3.55.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Natural Science Foundation Incubation Program of The Second Affiliated Hospital of Anhui Medical University","award":["2021GMFY03"],"award-info":[{"award-number":["2021GMFY03"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-05228-1","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T14:15:02Z","timestamp":1779545702000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["p53 expression and NLR could recognize distinct subtypes of lung adenocarcinoma with high expression of PD-L1 (TPS\u2009\u2265\u200950%), defined with 22C3 antibody"],"prefix":"10.1007","volume":"17","author":[{"given":"Ming","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengqi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoliang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibo","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhong","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,23]]},"reference":[{"issue":"1","key":"5228_CR1","doi-asserted-by":"publisher","first-page":"24","DOI":"10.2174\/0113892029298721240627095839","volume":"26","author":"Q Ren","year":"2025","unstructured":"Ren Q, Ma H, Wang L, et al. Gene-knockdown Methods for Silencing Nuclear-localized Insulin Receptors in Lung Adenocarcinoma Cells: A Bioinformatics Approach. Curr Genomics. 2025;26(1):24\u201335.","journal-title":"Curr Genomics"},{"issue":"10","key":"5228_CR2","doi-asserted-by":"publisher","first-page":"877","DOI":"10.2174\/0109298665248928231018070825","volume":"30","author":"Y Enyu Yang","year":"2023","unstructured":"Enyu Yang Y, Hong C, Xuan, et al. Biomarker of Pulmonary Inflammatory Response in LUAD: miR-584-5p Targets RAB23 to Suppress Inflammation Induced by LPS in A549 Cells. Protein Pept Lett. 2023;30(10):877\u201390.","journal-title":"Protein Pept Lett"},{"issue":"3","key":"5228_CR3","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2174\/0115665232274223231017052707","volume":"24","author":"J Wang","year":"2024","unstructured":"Wang J, Sun L, Liu Y, et al. FIGNL1 Promotes Hepatocellular Carcinoma Formation via Remodeling ECM-receptor Interaction Pathway Mediated by HMMR. Curr Gene Ther. 2024;24(3):249\u201363.","journal-title":"Curr Gene Ther"},{"issue":"2","key":"5228_CR4","doi-asserted-by":"publisher","first-page":"211","DOI":"10.2174\/1874467215666220329212300","volume":"16","author":"Y Cai","year":"2023","unstructured":"Cai Y, Sheng Z, Dong Z, et al. EGFR Inhibitor CL-387785 Suppresses the Progression of Lung Adenocarcinoma. Curr Mol Pharmacol. 2023;16(2):211\u201316.","journal-title":"Curr Mol Pharmacol"},{"issue":"19","key":"5228_CR5","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823\u201333.","journal-title":"N Engl J Med"},{"issue":"10183","key":"5228_CR6","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","volume":"393","author":"TSK Mok","year":"2019","unstructured":"Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393(10183):1819\u201330.","journal-title":"Lancet"},{"issue":"12","key":"5228_CR7","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1016\/j.jtho.2021.07.027","volume":"16","author":"M Shirasawa","year":"2021","unstructured":"Shirasawa M, Yoshida T, Shimoda Y, et al. Differential immune-related microenvironment determines programmed cell death protein-1\/programmed death-ligand 1 blockade efficacy in patients with advanced NSCLC. J Thorac Oncol. 2021;16(12):2078\u201390.","journal-title":"J Thorac Oncol"},{"issue":"12","key":"5228_CR8","doi-asserted-by":"publisher","first-page":"5000","DOI":"10.1111\/cas.15144","volume":"112","author":"M Satouchi","year":"2021","unstructured":"Satouchi M, Nosaki K, Takahashi T, et al. First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset. Cancer Sci. 2021;112(12):5000\u201310.","journal-title":"Cancer Sci"},{"issue":"7","key":"5228_CR9","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1200\/JCO.18.00149","volume":"37","author":"M Reck","year":"2019","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, et al. Updated analysis of KEYNOTE-024:pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol. 2019;37(7):537\u201346.","journal-title":"J Clin Oncol"},{"issue":"9","key":"5228_CR10","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1097\/JTO.0000000000000630","volume":"10","author":"WD Travis","year":"2015","unstructured":"Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J Thorac Oncol. 2015;10(9):1243\u201360.","journal-title":"J Thorac Oncol"},{"issue":"4","key":"5228_CR11","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.21037\/tlcr-19-583","volume":"9","author":"GL Banna","year":"2020","unstructured":"Banna GL, Signorelli D, Metro G, et al. Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab. Transl Lung Cancer Res. 2020;9(4):1533\u201342.","journal-title":"Transl Lung Cancer Res"},{"issue":"1","key":"5228_CR12","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/1759-7714.12917","volume":"10","author":"J Lee","year":"2019","unstructured":"Lee J, Park CK, Yoon HK, et al. PD-L1 expression in ROS1-rearranged non-small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1. Thorac Cancer. 2019;10(1):103\u201310.","journal-title":"Thorac Cancer"},{"key":"5228_CR13","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.lungcan.2020.10.009","volume":"150","author":"C Zeng","year":"2020","unstructured":"Zeng C, Gao Y, Xiong J, et al. Tumor-infiltrating CD8\u2009+\u2009T cells in ALK-positive lung cancer are functionally impaired despite the absence of PD-L1 on tumor cells. Lung Cancer. 2020;150:139\u201344.","journal-title":"Lung Cancer"},{"key":"5228_CR14","doi-asserted-by":"publisher","first-page":"1051168","DOI":"10.3389\/fgene.2022.1051168","volume":"13","author":"X Liang","year":"2022","unstructured":"Liang X, Yin Y, Li N. GOLM1 is related to the inflammatory\/immune nature of uveal melanoma and acts as a promising indicator for prognosis and immunotherapy response. Front Genet. 2022;13:1051168.","journal-title":"Front Genet"},{"issue":"2","key":"5228_CR15","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1002\/path.2744","volume":"222","author":"M K\u00f6bel","year":"2010","unstructured":"K\u00f6bel M, Reuss A, du Bois A, et al. The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. J Pathol. 2010;222(2):191\u201398.","journal-title":"J Pathol"},{"issue":"4","key":"5228_CR16","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1111\/j.1365-2559.2011.03907.x","volume":"59","author":"WG McCluggage","year":"2011","unstructured":"McCluggage WG, Soslow RA, Gilks CB. Patterns of p53 immunoreactivity in endometrial carcinomas: \u2018all or nothing\u2019 staining is of importance. Histopathology. 2011;59(4):786\u201388.","journal-title":"Histopathology"},{"issue":"5","key":"5228_CR17","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.annonc.2020.01.065","volume":"31","author":"AJ Schoenfeld","year":"2020","unstructured":"Schoenfeld AJ, Rizvi H, Bandlamudi C, et al. Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas. Ann Oncol. 2020;31(5):599\u2013608.","journal-title":"Ann Oncol"},{"issue":"2","key":"5228_CR18","doi-asserted-by":"publisher","first-page":"737","DOI":"10.21037\/tlcr-20-958","volume":"10","author":"N Frost","year":"2021","unstructured":"Frost N, Kollmeier J, Vollbrecht C, et al. KRASG12C\/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (\u2265\u200950%) lung adenocarcinoma. Transl Lung Cancer Res. 2021;10(2):737\u201352.","journal-title":"Transl Lung Cancer Res"},{"issue":"7528","key":"5228_CR19","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568\u201371.","journal-title":"Nature"},{"issue":"8","key":"5228_CR20","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1038\/s41416-018-0220-9","volume":"119","author":"JD Fumet","year":"2018","unstructured":"Fumet JD, Richard C, Ledys F, et al. Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy. Br J Cancer. 2018;119(8):950\u201360.","journal-title":"Br J Cancer"},{"issue":"24","key":"5228_CR21","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1200\/JCO.2016.71.9476","volume":"35","author":"S Peters","year":"2017","unstructured":"Peters S, Gettinger S, Johnson ML, et al. Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death ligand 1-selected advanced non-small-cell lung cancer (BIRCH). J Clin Oncol. 2017;35(24):2781\u201389.","journal-title":"J Clin Oncol"},{"issue":"7","key":"5228_CR22","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/0167-5699(95)80152-9","volume":"16","author":"G Berke","year":"1995","unstructured":"Berke G. Unlocking the secrets of CTL and NK cells. Immunol Today. 1995;16(7):343\u201346.","journal-title":"Immunol Today"},{"issue":"17","key":"5228_CR23","doi-asserted-by":"publisher","first-page":"13682","DOI":"10.18632\/oncotarget.24455","volume":"9","author":"M Albitar","year":"2018","unstructured":"Albitar M, Sudarsanam S, Ma W, et al. Correlation of MET gene amplification and TP53 mutation with PD-L1 expression in non-small cell lung cancer. Oncotarget. 2018;9(17):13682\u201393.","journal-title":"Oncotarget"},{"key":"5228_CR24","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.lungcan.2018.02.005","volume":"118","author":"P Serra","year":"2018","unstructured":"Serra P, Petat A, Maury JM, et al. Programmed cell death-ligand 1 (PD-L1) expression is associated with RAS\/TP53 mutations in lung adenocarcinoma. Lung Cancer. 2018;118:62\u20138.","journal-title":"Lung Cancer"},{"issue":"6","key":"5228_CR25","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1097\/PGP.0000000000000930","volume":"42","author":"P Nana Matsumoto","year":"2023","unstructured":"Nana Matsumoto P, Manrai D, Rottmann, et al. Correlative assessment of p53 immunostaining patterns and TP53 mutation status by next-generation sequencing in high-grade endometrial carcinomas. Int J Gynecol Pathol. 2023;42(6):567\u201375.","journal-title":"Int J Gynecol Pathol"},{"issue":"22","key":"5228_CR26","doi-asserted-by":"publisher","first-page":"5710","DOI":"10.1158\/1078-0432.CCR-18-0163","volume":"24","author":"J Biton","year":"2018","unstructured":"Biton J, Mansuet-Lupo A, P\u00e9cuchet N, et al. TP53, STK11, and EGFR mutations predict tumor immune profile and the response to Anti-PD-1 in lung adenocarcinoma. Clin Cancer Res. 2018;24(22):5710\u201323.","journal-title":"Clin Cancer Res"},{"key":"5228_CR27","doi-asserted-by":"crossref","unstructured":"Tavakkoli M, Wilkins CR, Mones JV, A Novel Paradigm Between Leukocytosis, Secretion G-CSF et al. Neutrophil-to-Lymphocyte Ratio, Myeloid-Derived Suppressor Cells, and Prognosis in Non-small Cell Lung Cancer. Front Oncol 2019; 9: 295.","DOI":"10.3389\/fonc.2019.00295"},{"issue":"5","key":"5228_CR28","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1158\/0008-5472.CAN-15-1439","volume":"76","author":"S Koyama","year":"2016","unstructured":"Koyama S, Akbay EA, Li YY, et al. STK11\/LKB1 deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T-cell activity in the lung tumor microenvironment. Cancer Res. 2016;76(5):999\u20131008.","journal-title":"Cancer Res"},{"key":"5228_CR29","doi-asserted-by":"publisher","first-page":"175883401774974","DOI":"10.1177\/1758834017749748","volume":"10","author":"N Karachaliou","year":"2018","unstructured":"Karachaliou N, Gonzalez-Cao M, Crespo G, et al. Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients. Ther Adv Med Oncol. 2018;10:1758834017749748.","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"5228_CR30","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1186\/s12974-018-1330-2","volume":"15","author":"J Qian","year":"2018","unstructured":"Qian J, Wang C, Wang B, et al. The IFN-\u03b3\/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1\/PD-L1 therapy. J Neuroinflammation. 2018;15(1):290.","journal-title":"J Neuroinflammation"},{"issue":"7664","key":"5228_CR31","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nature23270","volume":"547","author":"RT Manguso","year":"2017","unstructured":"Manguso RT, Pope HW, Zimmer MD, et al. In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature. 2017;547(7664):413\u201318.","journal-title":"Nature"},{"issue":"2","key":"5228_CR32","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.cell.2016.08.069","volume":"167","author":"JJ Gao","year":"2016","unstructured":"Gao JJ, Shi LZ, Zhao H, et al. Loss of IFN-gamma pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell. 2016;167(2):397\u2013404.","journal-title":"Cell"},{"issue":"9","key":"5228_CR33","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1604958","volume":"375","author":"JM Zaretsky","year":"2016","unstructured":"Zaretsky JM, Garcia-Diaz A, Shin DS, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016;375(9):819\u201329.","journal-title":"N Engl J Med"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-05228-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05228-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05228-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T11:02:26Z","timestamp":1784286146000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-05228-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,23]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5228"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-05228-1","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,23]]},"assertion":[{"value":"22 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Ethics Committee (EC) of The Second Affiliated Hospital of Anhui Medical University (Ethics Code: YX2025-092). The EC at The Second Hospital of Anhui Medical University acted as the central EC, whose review was accepted by the other participating institutions\u2019 EC. Informed consent to use histopathological samples for research purposes was obtained from all patients prior to surgery. This study was conducted in accordance with the Declaration of Helsinki. The study was approved by the Ethics Committee (EC) of The Second Affiliated Hospital of Anhui Medical University (Ethics Code: YX2025-092). All participants provided written informed consent prior to participating. Written informed consent was obtained from a legally authorized representative for anonymised patient information to be published in this article.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants provided written informed consent for publication of this article. All authors of the manuscript have read and agreed to its content and are accountable for all aspects of the accuracy and integrity of the manuscript.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1036"}}